Colorectal cancer affects many lives, and finding better treatments is crucial. A new study is looking at SHR-8068 injection combined with other therapies to see if it can improve outcomes for patients. The focus is on safety, tolerability, and effectiveness, which are key factors in treatment success. With an estimated 200 participants, this research could lead to important advancements in how we treat colorectal cancer. If successful, it may offer hope to those battling this challenging illness, potentially leading to better survival rates and quality of life.
Phase II Study on SHR-8068 Injection in Colorectal Cancer Now RecruitingCould a new treatment help fight colorectal cancer more effectively?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Recruitment is ongoing for a Phase II trial on SHR-8068 in colorectal cancer.
A Phase II clinical trial is currently recruiting participants to evaluate the safety, tolerability, and efficacy of SHR-8068 injection in combination with Adebrelimab and Bevacizumab injections for colorectal cancer. The study aims to enroll an estimated 200 participants. The primary outcomes being assessed are Pathological Complete Response (pCR) and Progression-Free Survival (PFS). The trial is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and is set to start on July 22, 2025, with a primary completion date of October 2031. This study will provide insights into the potential benefits of combining these treatments in managing colorectal cancer.
What this means for you:
SHR-8068 injection may offer new hope for colorectal cancer patients when combined with existing therapies. More on Cancer
Angiogenesis inhibitors combined with chemotherapy improve progression-free survival in advanced breast cancer patients
Adding angiogenesis inhibitors to chemotherapy helps advanced breast cancer patients stay disease-free longer
This systematic review and meta-analysis of phase II and III trials evaluated angiogenesis inhibitors combined with chemotherapy versus chem…
A large review of eight thousand four hundred patients found that adding angiogenesis inhibitors to standard chemotherapy improved how long …
Meta-analysis shows bevacizumab plus FOLFOX improves response rates without increasing common toxicities in advanced colorectal cancer
Adding bevacizumab to standard chemo improves tumor response in advanced colorectal cancer
This systematic review and meta-analysis evaluated bevacizumab combined with FOLFOX versus FOLFOX alone in patients with advanced or metasta…
A large review found that adding bevacizumab to standard chemotherapy improves how well tumors respond and keeps disease under control longe…
Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers
New drug combos target hidden cancer switches to stop resistance
This narrative review examines ovarian cancer management involving olaparib, bevacizumab, and durvalumab.
Hidden chemical changes in ovarian cancer cells help them hide from drugs, but new combinations might finally stop them from adapting and gr…
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients
Chemo before surgery may reduce tumor burden in colorectal cancer patients
This phase II randomized controlled trial evaluated 53 patients with resectable peritoneal metastasis of colorectal cancer.
A trial suggests chemo before surgery might lower tumor markers for colorectal cancer patients with spread to the abdomen.
View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Colorectal Cancer
Intervention(s): SHR-8068 Injection (DRUG), Adebrelimab Injection (DRUG), Bevacizumab Injection (DRUG)
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.
Primary Outcome(s): Pathological Complete Response (pCR); Progression Free Survival (PFS)
Enrollment: 200 (ESTIMATED)
Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Start: 2025-07-22 | Primary Completion: 2031-10
Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis
TyG Index Linked to Higher Fatty Liver Risk
Related in Gastroenterology
Acupuncture modulates the microbiota-gut-brain axis to remodel microbial structure in patients with irritable bowel syndrome
Acupuncture May Help Manage Irritable Bowel Syndrome Symptoms
This systematic review examines how acupuncture influences the microbiota-gut-brain axis in patients with irritable bowel syndrome. The auth…
New research suggests acupuncture may help manage irritable bowel syndrome by improving gut bacteria and balancing the gut-brain connection.
Reduced Shannon index indicates lower alpha-diversity in the gut microbiota of patients with primary biliary cholangitis
Gut Microbiota Differences Linked to Primary Biliary Cholangitis
This meta-analysis of 1,057 participants found that patients with primary biliary cholangitis have significantly lower Shannon index values …
A large review of patient data shows that people with primary biliary cholangitis have significantly lower gut bacterial diversity than heal…
Probiotic supplementation may improve salivary buffering and reduce cariogenic bacteria
A review of six studies shows probiotics may help oral and gut health in people
This systematic review of 6 reviews suggests probiotic supplementation may improve salivary buffering capacity and plaque pH, reduce Strepto…
This review looked at six studies on probiotic supplements. Results suggest better saliva function and fewer bad mouth bacteria, though stud…
Balloon-assisted ESD shows comparable outcomes to conventional ESD for colorectal polyps
Balloon-assisted endoscopic submucosal dissection shows shorter procedure time in RCTs
This systematic review and meta-analysis of 1449 patients found that balloon-assisted endoscopic submucosal dissection (BA-ESD) and conventi…
A meta-analysis of 1,449 patients found balloon-assisted endoscopic submucosal dissection had shorter procedure times in randomized trials, …
From Other Specialties
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Heterogeneous definitions and clinical inconsistencies currently hinder the accurate identification of treatment-resistant depression
New ways to define treatment resistant depression are emerging
This narrative review examines the phenotypic definition of treatment-resistant depression (TRD) and its associated biological correlates. T…
Doctors struggle to treat some types of depression because the current definition is inconsistent. New research looks at how biology and beh…
HIFU combined with ethanol ablation or GnRH-a improves intraoperative outcomes for adenomyosis treatment
HIFU Combined With Medication Shows Better Results for Adenomyosis
This network meta-analysis of 1,685 patients evaluated HIFU combined with various medications compared to HIFU alone for adenomyosis. The an…
Combining high-intensity focused ultrasound (HIFU) with specific medications may improve treatment outcomes for people with adenomyosis.
Risk-optimized use of Janus kinase inhibitors in Japanese patients with rheumatoid arthritis depends on comorbidities
New evidence helps doctors choose safer arthritis treatments for seniors
This narrative review examines the safety and risk profile of Janus kinase inhibitors (JAKi) for rheumatoid arthritis specifically within th…
Doctors are moving toward personalized plans for rheumatoid arthritis, focusing on a patient's specific health risks rather than just their …